What is subependymal giant cell astrocytoma?
Subependymal giant cell astrocytoma (SEGA) is a slow-growing, non-cancerous (benign) brain tumour that occurs almost only in people with tuberous sclerosis complex (TSC). TSC is a genetic condition that causes benign growths in many organs, including the brain, skin, kidneys, heart and lungs.
SEGAs grow on the wall of the fluid-filled spaces of the brain (the ventricles), usually near a narrow passage called the foramen of Monro. Here, cerebrospinal fluid flows from one ventricle to the next. A growing SEGA can block this passage, causing fluid to build up in the brain (hydrocephalus), which can be dangerous.
SEGAs develop in about one in ten to one in five people with TSC, mostly during childhood and the teenage years. They rarely start after the age of 25. The World Health Organization classes SEGA as a CNS WHO grade 1 tumour, the lowest grade.
There are two main treatments: surgery to remove the tumour and everolimus, a tablet that targets the faulty growth signal behind TSC (Franz et al., 2013).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Benign, slow-growing brain tumour (CNS WHO grade 1) |
| Linked condition | Tuberous sclerosis complex in nearly all cases |
| How common | About 5-20% of people with TSC |
| Typical age | Childhood and adolescence, usually before 20-25 |
| Location | Wall of the lateral ventricles near the foramen of Monro |
| Main danger | Blockage of fluid flow, causing hydrocephalus |
| Genes involved | TSC1 or TSC2 |
| Main treatments | Surgery or everolimus (an mTOR inhibitor) |
| Outlook | Very good with monitoring and timely treatment |
2. Tuberous sclerosis complex in brief
| Feature | Details |
|---|---|
| Cause | A change in the TSC1 or TSC2 gene |
| Inheritance | Can be inherited (autosomal dominant) or arise for the first time in a child |
| Brain features | Tubers, subependymal nodules and SEGAs |
| Other features | Epilepsy, learning difficulties, autism, skin patches, kidney angiomyolipomas, heart rhabdomyomas, lung changes |
| Mechanism | Loss of TSC function switches on the mTOR growth pathway |
Subependymal nodules are small, harmless bumps on the ventricle walls found in most people with TSC. A SEGA is thought to grow from one of these nodules. A nodule near the foramen of Monro that is over 1 cm or keeps growing is usually regarded as a SEGA.
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Tuberous sclerosis complex | The main and almost only risk factor |
| TSC2 gene change | Often linked with more severe TSC features |
| Younger age | Most SEGAs appear and grow in childhood |
| Growing subependymal nodules | Nodules near the foramen of Monro need closer monitoring |
In TSC, both copies of the TSC1 or TSC2 gene are lost in the tumour cells. This removes a brake on the mTOR pathway, which controls cell growth, so cells grow larger and divide more. This is why mTOR inhibitors such as everolimus can shrink SEGAs.
4. How does it look
On MRI
| Feature | Description |
|---|---|
| Location | Near the foramen of Monro, in the lateral ventricle |
| Size | Usually over 1 cm; may grow slowly over months or years |
| Enhancement | Bright after contrast injection |
| Calcification | Often contains calcium, best seen on CT |
| Hydrocephalus | Enlarged ventricles if fluid flow is blocked |
Under the microscope
| Feature | Description |
|---|---|
| Cells | Large cells, some looking like nerve cells and others like astrocytes |
| Pattern | Sheets and clusters, often arranged around blood vessels |
| Cell division | Rare |
| Markers | Mixed glial and neuronal markers, reflecting its glioneuronal nature |
Despite the name “astrocytoma”, SEGA behaves very differently from aggressive gliomas. It does not spread through the brain or to other parts of the body.
5. Symptoms
Many SEGAs are found on routine MRI scans before they cause symptoms. Symptoms usually come from raised pressure inside the head when fluid flow is blocked.
Symptoms of raised pressure (hydrocephalus)
- Headaches, often worse in the morning or on lying down
- Nausea and vomiting
- Drowsiness or reduced alertness
- Blurred or double vision
- Irritability or changes in behaviour
- In babies, an enlarging head or a bulging soft spot
Other symptoms
| Symptom | Notes |
|---|---|
| Worsening seizures | May reflect raised pressure or the tumour itself |
| Changes in learning or behaviour | Can be subtle and gradual |
| Weakness | Uncommon |
When to seek urgent help
Seek emergency care if a person with TSC develops a severe headache, repeated vomiting, unusual sleepiness, sudden vision problems or a change in seizure pattern. Sudden blockage of fluid flow can be life-threatening.
People with TSC may have communication difficulties, so carers should watch for changes in behaviour, sleep or feeding that might signal a problem.
Emergency plan
Families of people with TSC and SEGA are often given a written emergency plan. It usually includes:
- The warning signs of raised pressure
- The name and number of the neurosurgical or TSC team
- A summary of the person’s diagnosis, medicines and recent scans
- Instructions to tell emergency staff that the person has a SEGA and may need an urgent brain scan
6. Diagnosis
| Test | Purpose |
|---|---|
| Brain MRI with contrast | The main test for detecting and monitoring SEGA |
| CT scan | Shows calcification; used in emergencies |
| Eye examination | Checks for swelling at the back of the eye (papilloedema) |
| Genetic testing | Confirms TSC1 or TSC2 change |
| Neurological examination | Assesses symptoms and signs |
Surveillance in tuberous sclerosis complex
International TSC guidelines recommend regular brain MRI for people with TSC without symptoms, typically every 1-3 years until about age 25. Scans are done more often if a nodule is growing or if the ventricles are enlarging.
7. Treatment
Treatment depends on the size and growth of the tumour, whether there is hydrocephalus, and the person’s wider TSC features. Decisions are made by a TSC clinic or neuro-oncology team.
Options
| Option | When used |
|---|---|
| Monitoring | Small, stable SEGAs without symptoms |
| Surgery | Acute hydrocephalus, rapidly growing tumours, or when complete removal is achievable |
| Everolimus | Growing SEGAs, tumours in hard-to-reach places, or people who prefer to avoid surgery |
| Shunt or endoscopic procedure | To drain fluid when hydrocephalus is present |
| Laser ablation or radiosurgery | Occasionally, in specialist centres |
Surgery
Surgery aims to remove the whole tumour and restore normal fluid flow. It is the preferred option for sudden, severe hydrocephalus.
| Outcome (pooled surgical series) | Result |
|---|---|
| Complete removal | About 81% of operations |
| Recurrence | About 12%, usually after partial removal |
| Permanent complications | About 6% |
| Death | About 5% |
These figures come from a review of 18 surgical series including 263 patients (Danassegarane et al., 2022). Results in modern specialist centres can be better.
Surgery or everolimus?
| Factor | Surgery | Everolimus |
|---|---|---|
| Speed of effect | Immediate relief of blockage | Gradual shrinkage over months |
| Best for | Sudden hydrocephalus; a single, accessible tumour | Growing tumours, several TSC problems, high surgical risk |
| Duration | One operation, sometimes repeated | Usually long-term daily tablets |
| Main risks | Bleeding, infection, brain injury, need for a shunt | Mouth ulcers, infections, metabolic changes |
| Other TSC benefits | None | May also help seizures, kidney and skin lesions |
What brain surgery involves
| Stage | What happens |
|---|---|
| Before | MRI planning, blood tests and an anaesthetic review |
| Operation | Through an opening in the skull, often via the corpus callosum or a small opening in the brain surface; endoscopic surgery for some tumours |
| After | A day or more in intensive care, then the ward |
| Hospital stay | Usually around a week |
| Recovery | Gradual return to school or work over several weeks |
Everolimus
Everolimus is a tablet taken once a day. The dose is adjusted using blood level tests.
| Trial result | Finding |
|---|---|
| EXIST-1 (117 patients) | 35% had at least a halving of SEGA volume with everolimus, compared with none on placebo |
| Extension (111 patients) | About half achieved at least a halving of SEGA volume over a median of more than 2 years |
Results from Franz et al. (2013) and Franz et al. (2014). Everolimus can also reduce seizures and shrink kidney angiomyolipomas in TSC. SEGAs often regrow if the drug is stopped, so treatment is usually long-term.
Side effects of everolimus
| Side effect | Notes |
|---|---|
| Mouth ulcers and sore mouth (stomatitis) | The most common; special mouthwashes help |
| Infections | Colds, chest infections; report fever promptly |
| Raised cholesterol and blood sugar | Checked with blood tests |
| Rash or acne-like spots | Usually mild |
| Irregular periods | In some girls and women |
| Delayed wound healing | Treatment may be paused around surgery |
8. Outlook (prognosis)
| Situation | Outlook |
|---|---|
| Small SEGA under monitoring | Excellent; many never need treatment |
| SEGA treated with surgery | Usually very good when completely removed |
| SEGA treated with everolimus | Tumour control in most people while on treatment |
| Untreated growing SEGA | Risk of hydrocephalus and serious harm |
SEGA does not turn into cancer. For most people with TSC, long-term health depends more on epilepsy, learning and behaviour and kidney and lung involvement than on the SEGA itself.
SEGA in adults
Most SEGAs are found in children, but adults with TSC may still have one that was found earlier, or occasionally a newly growing lesion. Adult SEGAs tend to grow very slowly, and many simply need monitoring. Adults moving from children’s services should make sure their brain scans continue at the interval recommended by their TSC team.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Brain MRI | Every few months after starting treatment, then yearly or less often |
| Everolimus blood levels | Adjust the dose |
| Blood tests | Cholesterol, sugar, blood count, liver and kidney function |
| Eye checks | If hydrocephalus is suspected |
| TSC clinic review | Coordinates care for all TSC features |
10. Living with SEGA and tuberous sclerosis complex
- Attend regular TSC clinic appointments, which coordinate brain, kidney, skin, eye and heart checks
- Know the warning signs of raised pressure and seek urgent help if they appear
- Look after mouth hygiene while taking everolimus; use a soft toothbrush and alcohol-free mouthwash
- Report fevers and infections promptly
- Keep vaccinations up to date, but check with the team before live vaccines while on everolimus
- Connect with TSC charities, which provide information, family support and research updates
Support at school and home
| Area | Ideas |
|---|---|
| Education | Individual learning plans and specialist support where needed |
| Seizures | A seizure care plan shared with school and carers |
| Behaviour and wellbeing | Assessment for TSC-associated neuropsychiatric disorders (TAND) |
| Family | Genetic counselling for parents and siblings |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is SEGA cancer? | No. It is a benign tumour that does not spread |
| Does everyone with TSC get SEGA? | No. Only a minority develop one |
| Can adults get SEGA? | New SEGAs after age 25 are rare, but existing ones need monitoring |
| Is everolimus lifelong? | Often long-term, because SEGAs may regrow if it is stopped |
| Can SEGA come back after surgery? | Sometimes, mainly if part of the tumour was left behind |
| Does SEGA cause epilepsy? | Seizures in TSC are mainly caused by tubers, but a growing SEGA can make them worse |
| Can everolimus be taken with seizure medicines? | Yes, but some seizure medicines change everolimus levels, so blood tests are needed |
| Is radiotherapy used? | Rarely, because SEGA is benign and radiation can cause long-term harm in TSC |
| Can my other children have TSC? | Genetic testing and counselling can assess this |
12. Questions to ask your care team
- Is the SEGA growing, and how fast?
- Is there any sign of hydrocephalus?
- Is surgery or everolimus better in my case?
- How often will I need MRI scans?
- What side effects should I watch for on everolimus?
- Will everolimus interact with my other medicines?
- Who should I call in an emergency?
Resources
- Danassegarane, G. et al. (2022) ‘Subependymal giant-cell astrocytoma: a surgical review in the modern era of mTOR inhibitors’, Neurochirurgie, 68(6), pp. 627-636.
- Franz, D.N. et al. (2013) ‘Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial’, The Lancet, 381(9861), pp. 125-132.
- Franz, D.N. et al. (2014) ‘Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study’, The Lancet Oncology, 15(13), pp. 1513-1520.
- National Cancer Institute (2026) Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.